Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
3 hedge funds and large institutions have $3.38M invested in Hepion Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
50% less capital invested
Capital invested by funds: $6.79M → $3.38M (-$3.41M)
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
-$17K |
| 2 |
EWA
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
|
-$10K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SBL
26
Sargent Bickham Lagudis
Boulder,
Colorado
| $1 | – | – | – |
|
|
EWA
27
Exencial Wealth Advisors
Oklahoma City,
Oklahoma
| – | -$10K | – | – |
|
|
28
Nomura Holdings
Tokyo,
Japan
| – | -$17K | – | – |
|
|
29
UBS Group
Zurich,
Switzerland
| – | -$5K | – | – |
|
HEPA Hedge Fund Activity: Q3 2016 in Review
3 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q3 2016, worth a combined $3.38M — down 50% from $6.79M a quarter earlier.
Fund positioning in HEPA was balanced in Q3 2016: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Nomura Holdings, cutting an estimated $17K.
- 3 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $3.38M of Hepion Pharmaceuticals stock for Q3 2016, down 50% quarter-over-quarter.
- 0 funds opened new Hepion Pharmaceuticals positions in Q3 2016 and 0 closed out.
- The largest Hepion Pharmaceuticals seller in Q3 2016 was Nomura Holdings, an estimated $17K sold.
Based on aggregated 13F filings for Q3 2016.